Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824972 | Clinical Therapeutics | 2016 | 7 Pages |
Abstract
Compared with pravastatin 40 mg daily, pitavastatin 4 mg provided superior reductions in atherogenic lipid parameters beyond LDL-C, including RLP-C. Future studies are needed investigate the clinical implications of lowering directly measured RLP-C as the principal target. ClinicalTrials.gov identifier: NCT01256476.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
P. Elliott MD, Seth S. MD, MHS, Parag H. MD, Steven R. MD, Joseph M. PhD, Ralph B. Sr., PhD, Craig A. MD, Peter P. MD, PhD,